BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parsons DW, Roy A, Plon SE, Roychowdhury S, Chinnaiyan AM. Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol 2014;32:2203-5. [PMID: 24958819 DOI: 10.1200/JCO.2013.54.8917] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Van Allen EM, Robinson D, Morrissey C, Pritchard C, Imamovic A, Carter S, Rosenberg M, McKenna A, Wu YM, Cao X, Chinnaiyan A, Garraway L, Nelson PS. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 2016;7:52888-99. [PMID: 27167109 DOI: 10.18632/oncotarget.9184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
2 Mody RJ, Prensner JR, Everett J, Parsons DW, Chinnaiyan AM. Precision medicine in pediatric oncology: Lessons learned and next steps. Pediatr Blood Cancer 2017;64. [PMID: 27748023 DOI: 10.1002/pbc.26288] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
3 Blackburn HL, Schroeder B, Turner C, Shriver CD, Ellsworth DL, Ellsworth RE. Management of Incidental Findings in the Era of Next-generation Sequencing. Curr Genomics 2015;16:159-74. [PMID: 26069456 DOI: 10.2174/1389202916666150317232930] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
4 Bonadio RC, Crespo JR, Estevez-Diz MDP. Ovarian cancer risk assessment in the era of next-generation sequencing. Ann Transl Med 2020;8:1704. [PMID: 33490216 DOI: 10.21037/atm-20-1582] [Reference Citation Analysis]
5 Marron JM, DuBois SG, Glade Bender J, Kim A, Crompton BD, Meyer SC, Janeway KA, Mack JW. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer 2016;63:1974-82. [PMID: 27429135 DOI: 10.1002/pbc.26137] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
6 Varga E, Chao EC, Yeager ND. The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance. Fam Cancer 2015;14:481-5. [PMID: 25712765 DOI: 10.1007/s10689-015-9790-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
7 Green RC, Goddard KAB, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH; CSER Consortium. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet 2016;98:1051-66. [PMID: 27181682 DOI: 10.1016/j.ajhg.2016.04.011] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 16.0] [Reference Citation Analysis]
8 Dong L, Wang W, Li A, Kansal R, Chen Y, Chen H, Li X. Clinical Next Generation Sequencing for Precision Medicine in Cancer. Curr Genomics 2015;16:253-63. [PMID: 27006629 DOI: 10.2174/1389202915666150511205313] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
9 Hamilton JG, Shuk E, Garzon MG, Rodríguez VM, Westerman J, Hay JL, Offit K, Robson ME. Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. JCO Precis Oncol 2017;1. [PMID: 31938761 DOI: 10.1200/PO.17.00182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, Wood S, Garraway L, Joffe S. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med 2016;18:1011-9. [PMID: 26866579 DOI: 10.1038/gim.2015.207] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 13.0] [Reference Citation Analysis]
11 Seifert BA, O'Daniel JM, Amin K, Marchuk DS, Patel NM, Parker JS, Hoyle AP, Mose LE, Marron A, Hayward MC, Bizon C, Wilhelmsen KC, Evans JP, Earp HS 3rd, Sharpless NE, Hayes DN, Berg JS. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clin Cancer Res 2016;22:4087-94. [PMID: 27083775 DOI: 10.1158/1078-0432.CCR-16-0015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
12 Pendrick DM, Oberg JA, Hsiao SJ, Chung WK, Koval C, Sireci A, Kuo JH, Satwani P, Glasser CL, Sulis ML, Mansukhani MM, Glade Bender JL. Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline. Cold Spring Harb Mol Case Stud 2019;5:a003889. [PMID: 30936199 DOI: 10.1101/mcs.a003889] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Stover DG, Reinbolt RE, Adams EJ, Asad S, Tolliver K, Abdel-Rasoul M, Timmers CD, Gillespie S, Chen JL, Ali SM, Collier KA, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Lee CN, Shapiro CL, Macrae ER, Ramaswamy B, Lustberg MB. Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions. JCO Precis Oncol 2019;3:PO. [PMID: 32923860 DOI: 10.1200/PO.19.00090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Gray PN, Vuong H, Tsai P, Lu HM, Mu W, Hsuan V, Hoo J, Shah S, Uyeda L, Fox S, Patel H, Janicek M, Brown S, Dobrea L, Wagman L, Plimack E, Mehra R, Golemis EA, Bilusic M, Zibelman M, Elliott A. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. Oncotarget 2016;7:68206-28. [PMID: 27626691 DOI: 10.18632/oncotarget.11910] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
15 Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med 2015;7:80. [PMID: 26221189 DOI: 10.1186/s13073-015-0203-x] [Cited by in Crossref: 162] [Cited by in F6Publishing: 146] [Article Influence: 23.1] [Reference Citation Analysis]
16 Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, Ginsburg GS, Wu AC. Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. J Pers Med 2018;8:E19. [PMID: 29772692 DOI: 10.3390/jpm8020019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Gray PN, Dunlop CL, Elliott AM. Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) 2015;7:1313-32. [PMID: 26193321 DOI: 10.3390/cancers7030837] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
18 Dodson CH. Attitudes of oncology nurses concerning pharmacogenomics. Per Med 2017;14:515-20. [PMID: 29749856 DOI: 10.2217/pme-2017-0034] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, Ni A, Thomas T, Benayed R, Ashraf A, Lincoln A, Arcila M, Stadler Z, Solit D, Hyman DM, Zhang L, Klimstra D, Ladanyi M, Offit K, Berger M, Robson M. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol 2016;2:104-11. [PMID: 26556299 DOI: 10.1001/jamaoncol.2015.5208] [Cited by in Crossref: 166] [Cited by in F6Publishing: 159] [Article Influence: 27.7] [Reference Citation Analysis]
20 Hamilton JG, Shuk E, Genoff MC, Rodríguez VM, Hay JL, Offit K, Robson ME. Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. J Oncol Pract 2017;13:e590-601. [PMID: 28628391 DOI: 10.1200/JOP.2016.020057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
21 Grandval P, Fabre A, Béroud C, Olschwang S. Consideration surrounding incidental findings throughout multigene panel testing in cancer genetics. Clin Genet 2016;89:267-8. [DOI: 10.1111/cge.12672] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]